Calypte sells Pepgen to focus on diagnostics:
This article was originally published in Clinica
Executive Summary
Calypte Biomedical has sold its 29% stake in Pepgen, a privately-owned therapy company, developing new forms of interferon for multiple sclerosis and hepatitis C, for $500,000. Alameda, California-based Calypte said that the divestment was based on the company's financial needs and the strategic commitment to focusing its efforts on diagnostics.